|
Patent landscape, scope, and claims: |
United States Patent 8,987,441: Scope, Claim Architecture, and Patent-Landscape Implications
What does US 8,987,441 claim in plain technical terms?
US 8,987,441 is a broad small-molecule composition-of-matter patent that claims a compound of Formula (I), plus pharmaceutically acceptable salts and solvates, with extensive allowance for substituent variation across multiple structural “modules.” The independent claim is Claim 1, and it is followed by narrower dependent claims that progressively constrain substituent classes, positions, and specific structural embodiments. The patent also claims pharmaceutical compositions and attributes them to anti-influenza activity and cap-dependent endonuclease inhibitory activity (Claims 31-32).
At a high level, Claim 1 covers:
- A core scaffold expressed by a large set of permitted substituent patterns using variables:
- PR0, PR1, PR2, PR3, PR4, PR5
- L (linker alkylene/alkenylene)
- K (often hydrogen or alkylene group)
- R1a, R2a, R3a
- B1/B2 (with B1 defined as NR7a and B2 as CR5aR6a)
- R5a, R6a, R7a with heterocycle-formation rules
- Y, Z (linker single bond or lower alkylene)
- A substitution framework with two “substitution menu” layers:
- Substituent group F (general substituent class allowed on PR groups and elsewhere)
- Substituent group C and an additional substituent set for other variables (C, D in heterocycle context)
- A set of explicit exclusions / carve-outs (notably a proviso excluding a specific case under one branch of the PR/R5/R6/R7 logic).
What is the claim hierarchy and what is its practical coverage shape?
Independent claim
- Claim 1: Formula (I) compound + salt/solvate.
- Claim 1 is the coverage anchor; everything else narrows from it.
Dependent claim ladder (high-level)
- Claims 2-5: constrain R1a (and sometimes other variables) to narrower enumerations.
- Claims 6-8: constrain R2a and R3a (allowed groups narrowed).
- Claims 9-12: constrain R5a, R6a, R7a classes and enable specific “named-group” embodiments (Claim 11-12 reference a “group shown below,” which implies defined structural examples in the specification).
- Claims 13-17: define a more specific configuration with constraints on R1a/R2a/R3a/B1/B2 and again apply the key exclusion proviso.
- Claims 18-21: narrow R7a to tricyclic heterocycles and specify preferred substituent patterns for R7a (including m = 0 to 6, then tightened to 0-2 under Claim 21).
- Claims 22-25: further constrain variables and enable heterocycle sizing (e.g., Claim 24: 5- to 7-membered heterocycle).
- Claims 25-29: define PR as selected from a set of specific substituent fragment patterns and then narrow PR0/PR1/PR3 composition.
- Claims 30-32:
- Claim 30: pharmaceutical composition containing a compound falling within certain claim subsets.
- Claim 31: composition exhibits anti-influenza activity.
- Claim 32: composition exhibits cap-dependent endonuclease inhibitory activity.
What are the core legal “scope levers” inside Claim 1?
Claim 1 uses multiple variable regions that function as scope levers. Each lever expands the claim’s reach by allowing substitutes from broad categories.
1) Linkers and positional freedom
- L is allowed to be “straight or branched lower alkylene” or “straight or branched lower alkenylene.”
- Z is “a single bond or straight or branched lower alkylene.”
These are typical “structural permutation” allowances that broaden equivalence under infringement: different linkers still fall within Formula (I) if they satisfy the defined range.
2) Permitted PR fragments (PR0/PR1/PR2/PR3 family)
Claim 1 defines multiple PR substituent fragment types with patterns that include:
- Acyl-type fragments: —C(═O)—PR0, —C(═O)—PR1
- Ester-type fragments: —C(═O)—O—PR2
- Multi-atom chains: —C(═O)—L-O—PR1, —CH2—O—L-O—PR3, —CH2—O—C(═O)—O—PR3, etc.
- Phosphonate-like patterns: —CH2—O—P(═O)(—OH)2 and —CH2—O—P(═O)(—OBn)2
- Specific exceptions: PR4(except for a benzyl group)
This architecture is a major breadth driver. Even if the core scaffold is constrained, the claim still permits a wide range of functional “tails” and spacer logic.
3) Scaffold substituent sets (R1a, R2a, R3a)
Claim 1 includes three major substitution positions/regions:
- R1a: hydrogen/halo/hydroxy/carboxy/cyano/formyl plus broad “lower alkyl optionally substituted by group C” and many complex amine/amide/sulfone-style RA patterns through Z-based fragments.
- R2a: hydrogen and similar broad group C categories, plus Z-linked sulfonamides/amides/urea-like patterns.
- R3a: similar but includes explicit Z-linked patterns like —Z—N(RC3)—C(═O)—RC4, —Z—N(RC5)—C(═O)—O—RC6, —Z—C(═O)—N(RC7)(RC8), etc.
Legal effect: infringement analysis turns into whether a competitor’s substitution scheme matches at least one permitted permutation of the variable logic.
4) Heterocycle-formation provisions using adjacent atoms
Claim 1 repeatedly states that certain pairs may be taken together with an adjacent atom to form heterocycles:
- Example: RA1 and RA2 “may be taken together with an adjacent atom to form heterocycle”
- Similar language appears for RB7/RB8, RC1/RC2, RB9/RB10, and for R5a/R6a/R7a combinations under B1/B2 logic.
This language expands scope to “ring-embedded” implementations without needing separate discrete definitions for each ring.
5) Critical carve-out / exclusion
Claim 1 includes a proviso with an explicit exclusion:
- “with a proviso that the following c) is excluded c) R5a, R6a, and R7a are all hydrogens;”
This matters in validity and infringement because it indicates the applicant recognized and removed at least one embodiment that would otherwise fall within the variable sets.
How do dependent claims narrow the space (what gets constrained, and where)?
R1a narrowing
- Claims 2-5 constrain R1a to specific enumerations or limited subsets (Claim 5: “wherein R1a is hydrogen, or carboxy”).
R2a narrowing
- Claim 6: restricts R2a to hydrogen or lower alkyl optionally substituted by C, plus specific ring-based and one explicit Z-N pattern.
- Claim 7: further tightens to hydrogen or lower alkyl.
R3a narrowing
- Claim 8 limits R3a to hydrogen or certain cyclic/alkyl categories.
B1/B2 and R5a/R6a/R7a constraints
- Claim 9 provides a broad list of permitted structures for R5a/R6a/R7a, including sulfone, sulfoxide, dicarbonyl-type, and multiple Z-based substituent patterns.
- Claim 10 forces a more specific relationship: R5a is hydrogen and R6a is hydrogen or lower alkyl and R7a must be lower alkyl or cyclic groups (or Z-C(RD7)(RD8)(RD9)).
- Claims 11-12 cite “a group shown below” and combine constraints into specific embodiments.
R7a tricyclic heterocycle focus
- Claims 18-19 restrict R7a to tricyclic heterocyclic groups, then tighten allowed substituent classes (halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, lower alkynyl, halogeno-lower-alkyl, lower alkyloxy in claim 18; and in claim 19, to halogen/lower alkyl/halogeno-lower-alkyl/lower alkyloxy).
- Claims 20-21 define a more specific R7a scaffold with m = 0 to 6 then m = 0 to 2.
Heterocycle size constraints
- Claim 24 specifies a structural rule: heterocycle formed by R3a and R6a must be 5- to 7-membered.
PR selection tightening
- Claims 25-29 narrow PR to selected fragment patterns and specify component roles:
- Claim 25 lists PR fragment candidates and appears to exclude some alternatives by omission in the set.
- Claim 27 restricts PR0 to lower alkyl, PR1 to carbocyclic or heterocyclic, and PR3 to lower alkyl/carbocyclic/heterocyclic.
- Claim 28 sets PR patterns plus a bundle of R1a/R2a/R3a/B1/B2 conditions.
What is claimed at the formulation and method-attribute level?
Pharmaceutical compositions
- Claim 30: pharmaceutical composition containing a compound according to certain claim subsets:
- “any one of claims 1-8, 10, 11, 12 and 16-29”
- This is a composition scope list that explicitly excludes some later claims not listed (e.g., claim 9 and claims 13-15 are not included in Claim 30 as written).
Activity attributes
- Claim 31: composition exhibits anti-influenza activity.
- Claim 32: composition exhibits cap-dependent endonuclease inhibitory activity.
These activity claims often map to the intended therapeutic mechanism: influenza replication requires cap-dependent endonuclease activity (viral polymerase complex). Under enforcement, the key is whether the claimed compounds are capable of inhibiting cap-dependent endonuclease and whether the composition as administered achieves that effect.
Claim scope summary: what competitors must avoid to reduce risk?
Given the broad Formula (I) variable framework, “design-around” needs to break at least one of the following:
- Core scaffold connectivity defined implicitly by the Formula (I) template (the most difficult path; typically defines chemical identity).
- PR tail classes and linker patterns (the patent includes many PR fragment variants; switching functional group identity or attachment logic that falls outside the PR enumerations can reduce risk).
- Substituent class lists (C, F) and R1a/R2a/R3a/Y/Z constraints (moving to substituents outside the permitted menu).
- The specific heterocycle formation rules and excluded “all hydrogen” combination (Claim 1 carve-out could be relevant if a competitor lands on the excluded embodiment logic).
- PR4 “except for a benzyl group” if PR4 is used by a competitor’s design.
Patent landscape analysis: what this claim set implies about overlap and potential contention
This response depends on the patent text provided by the user, but a full US landscape for US 8,987,441 requires bibliographic metadata (application number, assignee, publication family, priority dates) and patent database retrieval. Without those, a complete and accurate landscape cannot be produced.
What can be analyzed from the claim text itself (landscape-relevant)
Even without assignee and priority, Claim 1 strongly indicates the compound class targets influenza biology through cap-dependent endonuclease inhibition, which usually places it in the known competitive orbit of:
- influenza antivirals targeting viral polymerase complex function
- nucleoside analogs are common in influenza, but this claim’s structure is not presented as a nucleoside; it reads as a substituted heterocycle scaffold with PR fragments and sulfonamide/amide-like variable options typical of non-nucleoside inhibitors
Where contention likely arises
- Scope-by-structure breadth: Claim 1’s combinatorial variable lists can overlap multiple earlier scaffold families if they share the same “module” logic.
- Tail and linker substitutions: Many later claims (25-29) narrow PR fragment patterns, which often reflects either (a) the inventors’ strongest examples, or (b) differentiation from closer prior art by limiting PR fragments.
- Activity-linked composition claims: Claims 31-32 are composition activity attributes. Prior art overlap often turns on whether earlier patents already disclose the same compounds (or close structural analogs) in antiviral formulations and whether those compounds were reported to inhibit cap-dependent endonuclease.
Landscape gaps that cannot be filled from the provided record
A complete landscape requires:
- the patent’s assignee, inventor(s), and priority/filing dates
- the specification’s example compounds and test results
- the prosecution history (continuations, restriction, claim amendments)
- citations to examiner prior art and any related foreign families
The user-provided claim text does not include those fields, so a complete, evidence-based US landscape cannot be stated.
Key Takeaways
- US 8,987,441 is a broad Formula (I) composition-of-matter claim with extensive variable-driven breadth across linkers (L, Z), tails (PR0-PR5), and substituent menus (C, F) on R1a/R2a/R3a and ring-forming groups.
- Dependent claims materially narrow scope by:
- tightening R1a/R2a/R3a allowed classes,
- constraining R5a/R6a/R7a combinations and heterocycle formation,
- focusing R7a on tricyclic heterocycles with m-limited substitution,
- selecting specific PR fragment patterns (notably Claims 25-29 and especially 27-28).
- Composition claims (30-32) expand coverage to formulations containing qualifying compounds and assert anti-influenza and cap-dependent endonuclease inhibitory activity.
- The claim architecture is designed to capture multiple chemical embodiments under one template; design-around must break the Formula (I) template or move substituent/linker choices outside the enumerated sets.
FAQs
-
Is US 8,987,441 a method-of-treatment patent or a composition-of-matter patent?
It is primarily a composition-of-matter claim (Claim 1) with additional pharmaceutical composition claims (Claims 30-32).
-
What is the most important claim for enforcement?
Claim 1 is the broadest and the basis for all dependent claims.
-
Where does the claim breadth come from?
From the combinatorial variable allowances: PR fragments, linkers (L, Z), and large enumerations for substituents (C and F) across R1a/R2a/R3a and ring-forming logic.
-
Does the patent include any explicit exclusion?
Yes. Claim 1 contains a proviso excluding an embodiment where R5a, R6a, and R7a are all hydrogens (under the relevant c) branch).
-
What biological mechanism does the patent tie to its composition claims?
Cap-dependent endonuclease inhibition, linked to influenza (Claims 31-32).
References
- User-provided claim text for United States Patent 8,987,441 (Claims 1-32).
More… ↓
⤷ Start Trial
|
